Shanghai Huaota Biopharmaceutical (Huaota Biopharm) is a biologics developer founded in 2013 and majority-owned by Zhejiang pharmaceutical group Huahai Pharmaceutical (SHA: 600521), serving as the group's main platform for innovative biologics. Using genetic-engineering methods and proprietary dual-target technology, the company develops multifunctional antibodies and recombinant proteins targeting cancer and autoimmune diseases.
1
Round
1
Industry
5
Tags
Oct 15, 2026
Latest raise
Funding activity · 1 round
Oct 15, 2026
CNY 350M
Series B
Led by Yangtze River Delta Venture Capital Guidance Fund (长三角创业投资引导基金)
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
